[Treatment of hepatitis C virus infection in patients with concurrent human immunodeficiency virus infection].
Coinfection with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) is frequent. While it is still unclear whether HCV affects the course of HIV infection, there is ample evidence that concurrent HIV infection accelerates the progression of fibrosis and liver-related morbidity and mortality in HCV-infected patients. The treatment of HCV infection in patients with HIV/HCV coinfection has improved during the last few years, but the outcome appears to be poorer than the outcome in HCV monoinfected patients. In this article the epidemiological and clinical aspects of HCV/HIV coinfection are described, and the four major treatment trials are reviewed.
Peters
Lars
L
H:S Rigshospitalet, Epidemiklinikken M 5132, København Ø. larspeters@dadlnet.dk
Lindhardt
Bjarne Ørskov
BØ
D017088:AIDS-Related Opportunistic Infections / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D023241:Antiretroviral Therapy, Highly Active; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a